arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Clene Inc.

CLNN
$3.88 ▼ -0.24 (-5.83%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
28 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Clene Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $48.0M
Dividend Yield —
Revenue Growth 233.3% ↗
Op. Margin —
ROIC 74.5% ↘
FCF / Share $-0.21 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -0.71
info Valuation on last close. End-of-day price, Nov 5, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$90.00K
↑ +233.3% —
Net Income Profit after all expenses
$-8.09M
↓ -977.4% —
FCF / Share Free cash flow per share
$-0.21
↑ +46.3% —
Long-Term Debt Long-term obligations
$17.60M
↓ -0.5% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns ↑
100
Financial Health ↑
66
Cash Quality ↓
49

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 8 years · 28 quarters